A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Inclusion Criteria:

• An informed consent document signed and dated by the subject.

• Male or female individuals who are 18 to 65 years of age, inclusive

• Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50kg

• Heterosexually active male participants and their female partners of childbearingpotential must agree to use 2 effective birth control methods for the duration ofthe study and for 90 days after the last dose of study intervention.

• Females of childbearing potential must agree to use 2 effective birth controlmethods for the duration of the study and for 30 days after the last dose of studyintervention.

Exclusion Criteria:

• Clinically relevant evidence or history of illness or disease

• Clinically relevant risk factors for cardiovascular abnormalities

• Pregnant or nursing females

• History of febrile illness within 7 days prior to the first dose of study drug orsubjects with evidence of active infection

• Infection with HIV, HBV, HCV, or SARS CoV 2

• Any condition possibly affecting drug absorption (e.g., gastrectomy,cholecystectomy)

• Before the first dose of study intervention, participant has received any vaccine,an investigational agent or biological product within 28 days or 5 times theterminal half-life (t½), whichever is longer

• A positive urine drug screen at Screening or Day -1

• Current tobacco smokers or use of tobacco within 3 months prior to Screening

• History of regular alcohol consumption